US20060014693A1

US20060014693A1 - Peptide inhibiting platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF) activity

Info

Publication number: US20060014693A1
Application number: US11/168,323
Authority: US
Inventors: Antonio Facchiano; Francesco Facchiano; Angelo Facchiano
Original assignee: Istituto Dermopatico dell'Immacolata; PROVINCIA ITALIANA DELLA CONGREGAZIONE DEI FIGLI
Current assignee: Istituto Dermopatico dell'Immacolata; PROVINCIA ITALIANA DELLA CONGREGAZIONE DEI FIGLI
Priority date: 2001-02-21
Filing date: 2005-06-29
Publication date: 2006-01-19
Also published as: AU2002241240B2; ITRM20010088A0; WO2002066498A3; US20020119931A1; EP1414855A2; ITRM20010088A1; US7009036B2; CA2451089A1; JP2004529103A; WO2002066498A2

Abstract

A novel peptide, derived from the human fibroblast growth factor (bFGF), is identified. Said molecule is able to inhibit in vitro the effects of Platelet Derived Growth Factor (PDGF-BB) and basic Fibroblast Growth Factor (bFGF) on primary rat smooth muscle cells (RASMC) and primary bovine endothelial cells (BAEC). Said molecule is also able to inhibit in vivo angiogenesis CD1 mice.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of co-pending application Ser. No. 10/077,746, filed on Feb. 20, 2002, the entire contents of which are hereby incorporated by reference.
The present invention concerns the identification and the synthesis of a peptide, derived from the basic human fibroblast growth factor (bFGF), having the following primary structure:
Asp-Pro-His-Ile-Lys-Leu-Gln-Leu-Gln-Ala-Glu hereafter referred to as PEP1 (SEQ ID NO: 1).
Said molecule, showing analogy with a sequence of bFGF, namely inhibits in vitro as well as in vivo PDGF-BB and bFGF effects.
More particularly, in vitro experimentation on primary rat smooth muscle cells (RASMC) and primary bovine endothelial cells (BAEC) indicated that said molecule is an efficient inhibitor of cell proliferation and migration at a dose that is not toxic for cells.
Moreover, in vivo experimentation carried out on reconstituted basement membrane plugs, subcutaneously injected in CD1 mice demonstrated that said molecule strongly inhibits bFGF-induced angiogenesis.
Reported results suggest that PEP1 might be used for the treatment of diseases with abnormal proliferation and migration of vascular cells such as restenosis after angioplasty, atherosclerosis, tumor growth and metastasis dissemination.
Growth factors, such as Platelet Derived Growth Factor (PDGF-BB) and basic Fibroblast Growth Factor (bFGF) play a crucial role in the proliferation and differentiation of many cell types. In fact, increased levels and/or activity of these factors occur in several pathologies, including tumor growth and blood-vessel diseases like atherosclerosis.
Platelet Derived Growth Factor (PDGF-BB) and basic Fibroblast Growth Factor (bFGF) are both essential for the phatogenesis of angiogenesis-related diseases since they directly modulate cell proliferation and migration within vascular wall—(Ross, R., et al. 1990, Science, 248, 1009-1012; Ross, R. 1993, Nature, 362, 801-809).
Angiogenesis is a key process for tissue development, as well as tumor growth and dissemination, It is controlled by several factors modulating cell differentiation, proliferation and migration (Holash, J., 1999, Oncogene, 18, 5356-5362; Zetter, B. R. et al., 1998, Annu. Rev. Med., 49, 407-424).
Several different molecules, such as antibodies neutralising PDGF and bFGF (Rutherford et al., Atherosclerosis, 1997, 45-51) and oligonucleotides inhibiting PDGF receptor expression (Sirois, M. G. et al., 1997, Circulation, 95, 669-676), were successfully used in vivo to inhibit diseases with abnormal proliferation and migration of vascular cells such as restenosis. Furthermore, specific inhibitors currently available are able to interfere with the receptor-binding or receptor dimerization or signaling (Heldin, C. H. et al., 1998, BBA, F79-F113).
PDGF and bFGF are required for tumor cells growth in vitro, growth of solid tumors in vivo, as well as metastases dissemination (Shawver, L. K. et al., 1997, Clin. Cancer Res., 3, 1167-1177; Vignaud, J. M. et al., 1994, Cancer Res., 54, 5455-5463; Chandler, L. A. et al., 1999, Int. J. Cancer, 81, 451-458; Westphal, J. R. et al., 2000, Int. J. Cancer, 15,86 (6), 768-776).
Inhibiting the activity and/or the signaling of PDGF and bFGF led to effective reduction of tumor growth and metastasis dissemination (Abramovich, R. et al., 1999, Br. J. Cancer, 79 (9-10), 1392-8; Bagheri-Yarmand, R. et al.,1998, Br. J. Cancer, 78 (1), 1118; Sola, F. et al, 1995, Invasion Metastasis, 15 (5-6), 222-231; Wang, Y. et al., 1997, Nature Med., 3, 887-893).
Therefore, specific antagonists of PDGF and bFGF are potential candidates for the treatment of proliferative diseases and angiogenesis-related disorders.
According to recent data collected by the same inventors, PDGF-BB and BFGF play an unsuspected role in the modulation of their pro-angiogenic functions. In particular, the inhibitory role of bFGF on cell proliferation and migration in addition to its pro-angiogenic effect, has been demonstrated (Facchiano, A. et al., 2000, J. Cell. Sci., 113, 2855-2863).
Moreover, the factors regulating the protein-folding and the structure-biological function relationship has been investigated (Ragone, R. et al., 1987, Italian J. of Biochem., 36, 306-309; Facchiano, F. et al., 1988, CABIOS, 4, 2, 303-305; Ragone, R. et al., 1989, Protein Engineering, 2, 7, 497-504; Facchiano, A. M. et al., 1989, CABIOS, 5, 4, 299-303; Facchiano, A. M. et al., 1991, CABIOS, 7, 3, 395- 396; Facchiano, A. et al., 1993, J. Mol. Evol., 36 (5), 448-457; Benvenga, S. et al., 1993, EOS-J. of Immunol. and Immunopharm., 13 (1), 18-19; Facchiano, A., 1995, J. Mol. Evol., 40, 570-577; Facchiano, A., 1996, Trends in Genetics, 12(5), 168-169; Scarselli, M. et al., 1997, J. Peptide Sci., 3, 1-9; Benvenga, S. et al., 1999, Amyloid, 6 (4), 250-255; Facchiano, A. M., 1999, Protein Eng., 12 (10),893; Pozzetto, U. et al., 2000, Transplant Int., Suppl. n. 1, 13, S306-S310; Facchiano, A. M., 2000, Bioinformatics, 16 (3), 292-293).
In the present invention, by investigating protein structure, regions of bFGF sequence potentially responsible of its biological activity have been identified. Among these regions, a peptide having the following primary structure:
Asp-Pro-His-Ile-Lys-Leu-Gln-Leu-Gln-Ala-Glu (SEQ ID NO: 1; here referred to as PEP1), derived from human bFGF turned out to be a strong inhibitor in vitro of bFGF, PDGF-BB and fetal calf serum (FCS) effects, such as cell proliferation and migration observed in primary rat smooth muscle cells (RASMC) and primary bovine endothelial cells (BAEC). Said activity has been observed at a dose as low as 10 nanograms/milliliter and PEP1 is not toxic at this dose in vitro. The heat-denatured and the scrambled version (with random aminoacid sequence) of PEP1 were used as control: both do not show any activity.
Moreover, PEP1 even show inhibitory activity in vivo; it is, indeed, able to inhibit angiogenesis in reconstituted basement membrane plugs, subcutaneously injected in CD1 mice.
Accordingly with what previously detected, PEP1 synthesis was achieved by automatic synthetizer, using the standard technique named f-moc.
After that, three different batches of PEP1 were tested and they gave similar results in the biological assays. Moreover, a scrambled version of the peptide (PEP1scr) was prepared and after used as negative control in all the experiments.
Several in vitro and in vivo test were carried out on said molecule and they revealed the functional characteristics of said peptide.
The results obtained are reported in the accompanying drawings:
FIG. 1 shows the results of dose-dependent experiments carried out on RASMC. RASMC proliferation induced by 10% FCS was evaluated after 48 hours, in the absence and in the presence of different PEP1 doses, ranging from 1 g/mi to 1 pg/ml;
FIG. 2A shows PEP1 and PEPscr effect on RASMC proliferation induced by PDGF-BB (10 ng/ml);
FIG. 2B shows PEP1 and PEP1scr effect on RASMC spontaneous proliferation in the presence of BSA;
FIG. 3A shows PEP1 and PEPscr effect on BAEC proliferation induced by PDGF-BB (10 ng/ml);
FIG. 3B shows PEP1 and PEP1scr effect on BAEC spontaneous proliferation in the presence of BSA;
FIG. 4A shows the effect in the presence or in the absence of PEP1 and PEPscr (10 ng/ml) on BAEC migration induced by FCS (1%);
FIG. 4B shows the effect in the presence or in the absence of PEP1 and PEPscr (10 ng/ml) on BAEC migration induced by PDGFD-BB (10 ng/ml);
FIG. 4C shows the effect in the presence or in the absence of PEP1 and PEPscr (10 ng/ml) on BAEC migration induced by bFGF (10 ng/ml);
FIG. 5A shows the effect in the presence or in the absence of PEP1 and PEPscr (10 ng/ml) on BAEC migration induced by EGF (10 ng/ml);
FIG. 5B shows the effect in the presence or in the absence of PEP1 and PEPscr (10 ng/ml) on BAEC migration induced by aFGF (10 ng/ml);
FIG. 5C shows the effect in the presence or in the absence of PEP1 and PEPscr (10 ng/ml) on BAEC migration induced by Fibronectin (10 ng/ml);
FIG. 5D shows the effect in the presence or in the absence of PEP1 and PEPscr (10 ng/ml) on BAEC migration induced by VEGF (10 ng/ml);
FIG. 6 shows PEP1 and PEP1scr effect on RASMC migration induced by PDGF-BB (10 ng/ml);
FIG. 7 shows PEP1 and PEP1scr effect on angiogenesis induced by bFGF in reconstituted basement membrane plugs, subcutaneusly injected in CD1 mice.

IN VITRO PEP1 ACTIVITY ASSAY

This test was carried out on Primary rat aorta smooth muscle cells (RASMC) obtained from six-month old male Wistar rats following a well known technique (Sterpetti, A. V. et al., 1992, J. Vasc. Surg., 6, 16-20); primary bovine aortic endothelial cells (BAEC) were obtained according to previously described protocols (D'Arcangelo, D. et al., 2000, Circ. Res.,86,312-318).

Migration Assay

Cell migration is a key process for the development of new blood-vessels. Consequently, PEP1 effect on cell migration induced by several different chemoattractant factors has been evaluated mainly on endothelial cells (BAEC). Migration assays were carried out in modified Boyden chambers (Neuroprobe Inc.), following known standard techniques (Albini, A. et al., 1995, Int. J. Cancer,61,121-129; Facchiano, A. et al., 2000, J. Cell. Sci., 113, 2855-2863). Cells were dispensed in the upper portion of the Boyden chamber. Chemoattractant factor were calf fetal serum (FCS) 10% or the following human recombinant factors: PDGF-BB, bFGF and vascular endothelial growth factor (VEGF). PEP1 PEPscr (scrambled control) diluted in water, were added to the growth factor solution at the reported final concentration. Thus chemotaxis induced by bFGF (10 ng/ml), or PDGF-BB (10 ng/ml), or FCS (2%), in the absence or in the presence of 10 ng/ml PEP1 and PEP1scr, was evaluated.
All the migration assays were carried out at 37° C. in 5% CO₂, for a total time of 5 hours; then filters were removed, fixed with absolute ethanol and stained with toluidine blue. Cells migrated were counted at 400× magnification in 15 fields for each filter and the average number of cell/field was reported. All the experiments were performed at least 3 times in duplicate.
The experiments show that, in every condition, PEP1 markedly inhibit, and in a rate more than 50%, BAEC migration, but PEP1scr do not have any effect (FIG. 4A, 4B e 4C). When bFGF or PDGF-BB were-tested, PEP1 was either dispensed in the lower and in the upper portion of the Boyden chamber; a slightly better inhibitory activity was observed when it was dispensed in the lower portion of the Boyden chamber.
In contrast, PEP1scr control does not show any activity when dispensed in both portion of the Boyden chamber. To evaluate the specificity of said inhibitory effect, PEP1 effect on other chemoattractans was tested. PEP1 and PEP1scr do not affect Endothelial cell migration induced by aFGF or VEGF or EGF or Fibronectin (FIGS. 5A, 5B, 5C and 5D), indicating that said molecule specifically affect bFGF and PDGF-BB.
Similar results were obtained in chemotaxis assays carried on RASMC induced by PDGF-BB and FCS. PEP1 inhibits RASMC migration (i.e. about 60%), while PEP1scr is inactive (FIG. 6).

Proliferation Assay

Proliferation assay was carried out on primary rat aorta SMC and on primary bovine aortic endothelial cells (BAEC). Cells were plated in six-well plates (1×10⁵cells/plate) and grown for 24 hours in Dulbecco Modified eagle's medium (DMEM) supplemented with 10% FBS, at 37° C. in 5% CO₂. Then, the medium was replaced with DMEM medium containing 0.1% BSA for 24 hours. Subsequently, the medium was replaced with fresh medium containing either 0.1% BSA alone or 0.1% BSA with growth factors at 10 ng/ml final concentration or fetal calf serum (FCS) al 10%, in the absence or in the presence of PEP1 or control peptide. Each assay was carried out for mounting period of time up to a maximum time of three days and the cell were harvested and counted with hemacytometer.
First of all, PEP1 was tested in dose-dependence experiments: RASMC proliferation induced by FCS 10%, was evaluated at 48 hours, in the presence and in the absence of different PEP1 doses, ranging from 1 μg/ml to 1 pg/ml (FIG. 1). The heat-denatured PEP1 and the scrambled version of PEP1 were used as control. PEP1 showed a dose-dependent inhibitory activity, which reached 60% inhibitory effect at 10 ng/ml, while the control peptides did not show any activity. Consequently, the dose of 10 ng/ml was chosen for the following in vitro experiments.
The effect of PEP1 was tested on proliferation induced by PDGF-BB and bFGF (10 ng/ml each), in RASMC and BAEC. FIG. 2A shows the marked inhibition of proliferation induced by PDGF-BB. In time course experiments, proliferation induced by PDGF-BB (10 ng/ml) was significantly inhibited in the presence of PEP1 at all time points. PEP1 block almost completely cell proliferation, while the control scrambled peptide (PEP1scr) is not effective at any time (FIG. 2A).
Spontaneous proliferation (in the presence of bovine serum albumin, BSA) is not significantly affected by PEP1 nor by PEP1scr at any time, indicating that both molecules are not toxic per se at the tested doses on RASMC (FIG. 2B), nor on BAEC (FIG. 3B) Moreover, PEP1 shows similar inhibitory effect on BAEC stimulated by bFGF (10 ng/ml) (FIG. 3A).
Then the following in vivo experiment was carried out:

Angiogenesis on Reconstituted Basement Membrane Plugs

Angiogenesis on reconstituted basement membrane plugs (named “Matrigel”, produced by Collaborative Biomedical Products, Beckton-Dickinson) was carried out as previously reported (Muhlhauser, J., 1995,J. Circ. Res.,77,1077-1086). Briefly, reconstituted basement membrane plugs added with bFGF (150 ng/ml) alone or in the presence of PEP1 (10 micrograms/ml) were subcutaneusly injected in CD1 mice (female, 19 weeks age). bFGF induces the formation of capillary network within 7 days, therefore plugs were excised 7 days after injection and included in paraffin. Obtained slides were stained with trichrome-Masson staining procedure and analysed with an optical image analizer and the number of vessels per mm²within plugs was quantified.
FIG. 7 shows that PEP1 acts as strong inhibitor of blood vessel formation induced by bFGF (i.e. 46% inhibition vs bFGF alone). 10 animals were used as control (treated with bFGF alone) and 14 animals were treated with bFGF in the presence of PEP1. This experiment shows that PEP1 is able to markedly inhibit new-blood vessel formation induced by bFGF and indicates PEP1 as a good candidate for further in vivo studies.
In conclusion:
1) PEP1 showed a strong and specific inhibitory activity on mitogenic and chemoattractive properties of platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF) in vitro.
2) Anti-angiogenic activity in vivo was demonstrated in assays carried out on reconstituted basement membrane plugs.
These results indicate PEP1 as a good candidate for further investigation on animal models of tumor growth and metastasis as well as other vascular-based diseases.

Claims

1. A method for inhibiting platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF) in a subject comprising administering to said subject an effective amount of a peptide, said peptide having the following primary structure:

Asp-Pro-His-Ile-Lys-Leu-Gln-Leu-Gln-Ala-Glu (Seq Id No: 1)

2. A method to affect cell proliferation in a subject comprising administering to said subject an effective amount of a peptide, said peptide having the following primary structure:

Asp-Pro-His-ILe-Lys-Leu-Gln-Leu-Gln-Ala-Glu (SEQ ID NO: 1).

3. The method according to claim 2, where said method inhibits cell migration and tumor cell migration toward potential metastasis sites comprising administering an effective amount of said peptide.

4. The method according to claim 2, wherein said method inhibits a primary tumor growth and metastasis comprising administering an effective amount of said peptide.

5. A method for the preparation of a pharmacological compound comprising adding a peptide of SEQ ID NO: 1 to an excipient.

6. A method for the treatment of vascular diseases in a subject comprising administering to said subject an effective amount of a peptide, said peptide having the following primary structure:

Asp-Pro-His-ILe-Lys-Leu-Gln-Leu-Gln-Ala-Glu (SEQ ID NO: 1).

7. The method according to claim 6, wherein thrombotic events and related pathologies in a subject are treated by administering to said subject an effective amount of said peptide.